| pubmed-article:10452348 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0021080 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0021079 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:10452348 | lifeskim:mentions | umls-concept:C0702240 | lld:lifeskim |
| pubmed-article:10452348 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:10452348 | pubmed:dateCreated | 1999-9-28 | lld:pubmed |
| pubmed-article:10452348 | pubmed:abstractText | Immunosuppression with corticosteroids and cyclosporine has been associated with hyperlipidemia, a risk factor for post-transplant coronary artery disease. The recent development of tacrolimus has created an alternative to cyclosporine-based triple drug immunotherapy. One potential benefit that has been reported in patients receiving tacrolimus is a minimization of elevation of both total and LDL cholesterol, compared to those increases observed in patients receiving cyclosporine-based immunosuppression. It is unclear in previous studies whether this beneficial effect is related to tacrolimus directly or to its corticosteroid sparing potential. To study this relationship, we compared lipid profiles from pediatric cardiac transplant recipients treated with corticosteroids, and either cyclosporine or tacrolimus. | lld:pubmed |
| pubmed-article:10452348 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10452348 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10452348 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10452348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10452348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10452348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10452348 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10452348 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10452348 | pubmed:issn | 1053-2498 | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:FrickerF JFJ | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:KubilisP SPS | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:WinterW EWE | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:KahlerD ADA | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:SchowengerdtK... | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:PensonM GMG | lld:pubmed |
| pubmed-article:10452348 | pubmed:author | pubmed-author:HarkerKK | lld:pubmed |
| pubmed-article:10452348 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10452348 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10452348 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10452348 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10452348 | pubmed:pagination | 707-13 | lld:pubmed |
| pubmed-article:10452348 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:meshHeading | pubmed-meshheading:10452348... | lld:pubmed |
| pubmed-article:10452348 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10452348 | pubmed:articleTitle | Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. | lld:pubmed |
| pubmed-article:10452348 | pubmed:affiliation | Department of Pediatrics, University of Florida College of Medicine, Gainesville 32610, USA. | lld:pubmed |
| pubmed-article:10452348 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10452348 | pubmed:publicationType | Comparative Study | lld:pubmed |
